Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Swiss study tests if pharmacy cannabis reduces smoking risks

NCT ID NCT06120855

Disease control Sponsor: University of Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether allowing regular cannabis users to buy regulated cannabis from pharmacies helps them switch to safer ways of using it, like vaping or edibles, instead of smoking. About 1,177 participants in Switzerland are randomly assigned to buy from pharmacies or stick with the illicit market for 6 months. The goal is to see if this reduces smoking and related health risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
regulated cannabis from authorized pharmacies
What this could lead to
If successful, this could show that regulated cannabis access reduces smoking-related harms and promotes safer consumption methods.
What could go wrong
This is an early-stage study with 1177 participants, and results may not apply to other regions. Participants may not stick to safer methods, and self-reported data can be unreliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,177 people

The number who actually took part.

Started

Mar 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years old (validated with valid identification document) * Written informed consent * Regular cannabis user: Self-reported cannabis use at least once a month over the last 6 months and verified cannabis exposure based on urine analysis at baseline * Resident status in the canton of Bern (for cannabis purchase in the cities of Bern or Biel) or in the city of Lucerne (for cannabis purchase in the city of Lucerne) (validated with registration confirmation from the municipality or confirmation of the residential address) Exclusion Criteria: * Pregnant women (pregnancy test based on urine sample) * Breastfeeding women (self-reported) * People with a prescription for medical cannabis (self-reported) * People currently in psychiatric inpatient treatment (self-reported) * People with current, severe psychosis (self-reported and confirmed by study nurse/study physician) * People with current, severe suicidal thoughts (self-reported and confirmed by study nurse/study physician) * Inability to follow the procedures of the study due to severe cognitive impairment or language problems * People who cannot attend the baseline study visit in-person * People planning to move out of the canton of residence within 6 months of entering the trial. * People who are participating or have participated (inclusion date up to one year ago) in another cannabis pilot trial which allows to buy regulated cannabis (validated by matching untraceable codes between studies witch the same catchment area).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence Marijuana Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis Cannabis use Marijuana smoking

Contacts and locations

Locations

  • University of Bern

    Bern, 3012, Switzerland

  • Zentrum für Hausarztmedizin und Community Care, University of Lucerne

    Lucerne, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.